PTK 2015 Banner 
2015 Peptalk M Banner 

Pipeline One Icon Pipeline One Header 

Cambridge Healthtech Institute’s 2nd Annual
Improving the Clinical Efficacy of Antibody Therapeutics
Cutting-Edge Protein Engineering for the Next Generation of
Safe and Effective Biotherapeutics

January 22-23, 2015


When the more than 350 therapeutic monoclonal antibodies in development advance into the clinic and to commercial launch, the quality of therapeutic response will become increasingly important to regulatory agencies and frugal payers. Regulators are demanding better data to support claims of safety and potency – and payers are seeking meaningful therapeutic benefits relative to existing standards of care before adding higher-cost biotherapeutics to formularies. The Improving the Clinical Efficacy of Antibody Therapeutics conference showcases state-of-the-art discovery and development-stage engineering strategies for improving the safety and effectiveness of this important class of biologic drugs.

Preliminary Agenda 


GLYCOENGINEERING AND ENHANCING EFFECTOR FUNCTION  

KEYNOTE PRESENTATION 

A Palette of Engineered Fc Domains for Optimal Antibody-Mediated Target Cell Clearing and Immunomodulation

George Georgiou, Ph.D., Professor, Cockrell Family Regent’s Chair in Engineering, Department of Biomedical Engineering, The University of Texas at Austin


Improving the Therapeutic Efficacy of pH and Calcium-Dependent Antigen Binding Antibodies

Tomoyuki Igawa, Ph.D., Group Manager, Discovery Research, Chugai Pharmaceutical Company


Glycoengineering Enhanced ADCC in a FGFR2b-Specific Antibody Treating Patients with Gastric Cancers

Kristen Pierce, Ph.D., Associate Director, Oncology, Five Prime Therapeutics

MODULATION OF COMPLEMENT ACTIVATION  

Complement Is Activated by IgG Hexamers Assembled at the Cell Surface

Janine Schuurman, Ph.D., Vice President, Research, Genmab


Cytotoxic Mechanisms of Immunotherapy: Harnessing Complement in the Action of Anti-Tumor Monoclonal Antibodies

Ronald P. Taylor, Ph.D., Professor of Biochemistry and Molecular Genetics Research, University of Virginia


COMBINATION STRATEGIES FOR ENHANCING THE EFFICACY OF ANTIBODY THERAPY  

Multi-Targeting Antibody Mixtures to Address Tumor Heterogeneity and Plasticity

Michael Kragh, Ph.D., Director, Preclinical Pharmacology & Toxicology, Symphogen A/S


Using an Oligoclonal Approach to Target HER3/ErbB3

Matthew Robinson, Ph.D., Assistant Professor, Fox Chase Cancer Center


Development of an Antibody Combination Therapeutic (ACT) for the Treatment of Ventilator Associated Pneumonia

Elizabeth Reczek, Ph.D., President and CSO, Excelimmune, Inc.


CHARACTERIZATION OF PROPERTIES IMPACTING EFFICACY  

Analytical Methods to Characterize the Binding Kinetics, Affinity, and Epitope of Therapeutic Antibodies

Yasmina Abdiche, Ph.D., Research Fellow, Rinat-Pfizer


Impact of Effector Cells on in vitro ADCC Activity of Therapeutic Antibodies

Shan Chung, Ph.D., Senior Scientist, Bioanalytical Sciences, Genentech, a Member of the Roche Group


Analytical Fc Receptor Affinity Chromatography for Functional Characterization of Monoclonal Antibodies

Tilman Schlothauer, Ph.D., Senior Scientist, Protein Analytics, Roche Diagnostics GmbH


STRATEGIES FOR IMPROVING THE EFFICACY OF ANTIBODY THERAPEUTICS  

Monoclonal Antibody Therapy for Multiple Myeloma

Frits van Rhee, M.D., Ph.D., Professor, Medicine; Director, Developmental and Translational Medicine, Myeloma Institute for Research and Therapy, University of Arkansas


Observations Regarding Antibody Pharmacokinetics and a Case Study; Engineering a mAb for Prolonged Half-Life to Better Assess an Animal Model Species

Tom Nesspor, Research Scientist, Biologics, Janssen


Antibodies that Target Bioactive Lipids

Jon Wojciak, Ph.D., Scientist, Lpath


Computational and Experimental Mapping of Deimmunized Biotherapeutic Design Space

Karl E. Griswold, Ph.D., Associate Professor, Bioengineering, Thayer School of Engineering, Dartmouth College